The war in Ukraine has been a test for the pharmaceutical industry, but one that senior leadership have responded to with compassion as well as censure. Many companies are providing financial donations and medical supplies and have pledged to work to address the health needs of everyone affected by the war.
At the same time, more than 400 biopharma leaders signed an open letter condemning the attack, calling for “economic disengagement” from Russia. While the messages are symbolic, they serve to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?